Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers

References

1. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000;12:30–44.10.1002/1520-6394(2000)12:1+<30::AID-DA4>3.0.CO;2-GSearch in Google Scholar

2. Sloan DM. Desvenlafaxine: frequently asked questions. Prim Psychiatry 2009;16:1–8.Search in Google Scholar

3. Howell SR, Husbands GE, Scatina JA, Sisenwine SF. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993;23:349–59.10.3109/00498259309057023Search in Google Scholar

4. McAlpine DE, Biernacka JM, Mrazek DA, O’Kane DJ, Stevens SR, Langman LJ, et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 2011;33:14–20.10.1097/FTD.0b013e3181fcf94dSearch in Google Scholar

5. Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999;20:480–90.10.1016/S0893-133X(98)00113-4Search in Google Scholar

6. Shams ME, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006;31: 493–502.10.1111/j.1365-2710.2006.00763.xSearch in Google Scholar

7. Lindh JD, Annas A, Meurling L, Dahl M-L, Al-Shurbaji A. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol 2003;59:401–6.10.1007/s00228-003-0627-xSearch in Google Scholar

8. Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012;26:39–67.10.2165/11594710-000000000-00000Search in Google Scholar

9. National Center for Biotechnology Information. Venlafaxine – PubChem. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5656. Accessed on 13 April, 2013.Search in Google Scholar

10. Whyte IM. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Q J Med 2003;96:369–74.10.1093/qjmed/hcg062Search in Google Scholar

11. Williams DA. Antidepressants. In: Thomas L. Lemke and David A. Williams, editors. Foye’s principles of medicinal chemistry. Philadelphia: Lippincott Williams & Wilkins, 2008:547–98.Search in Google Scholar

12. eMedExpert. Venlafaxine (Effexor). Available from: http://www.emedexpert.com/facts/venlafaxine-facts.shtml. Accessed on 13 April, 2013.Search in Google Scholar

13. Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatry Res 2008;42:22–34.10.1016/j.jpsychires.2007.01.008Search in Google Scholar

14. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10:732–47.10.1017/S1092852900019726Search in Google Scholar

15. Murrough JW, Charney DS. Is there anything really novel on the antidepressant horizon? Curr Psychiatry Rep 2012;14:643–9.10.1007/s11920-012-0321-8Search in Google Scholar

16. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166–74.10.1016/S0006-3223(02)01425-7Search in Google Scholar

17. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396–404.10.1192/bjp.180.5.396Search in Google Scholar PubMed

18. Mallinckrodt CH, Prakash A, Houston JP, Swindle R, Detke MJ, Fava M. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology 2007;56:73–85.10.1159/000111537Search in Google Scholar PubMed

19. Bauer M, Tharmanathan P, Volz H-P, Moeller H-J, Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009;259:172–85.10.1007/s00406-008-0849-0Search in Google Scholar PubMed

20. Thase ME. Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacol Bull 2008;41:58–85.Search in Google Scholar

21. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007;27:672–6.10.1097/jcp.0b013e31815a4412Search in Google Scholar PubMed

22. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234–41.10.1192/bjp.178.3.234Search in Google Scholar PubMed

23. Teter CJ, Kando JC, Wells BG PE. Depressive disorders. In: L. Michael Posey, Editor. Pharmacotherapy: a pathophysiologic approach, 7th ed. USA: The McGraw-Hill Companies 2008;1123–39.Search in Google Scholar

24. Ye W, Zhao Y, Robinson RL, Swindle RW. Treatment patterns associated with duloxetine and venlafaxine use for major depressive disorder. BMC Psychiatry 2011;11:19.10.1186/1471-244X-11-19Search in Google Scholar PubMed PubMed Central

25. Baldomero EB, Ubago JG, Cercós CL, Ruiloba JV, Calvo CG, López RP. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 2005;22:68–76.10.1002/da.20080Search in Google Scholar PubMed

26. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905–17.10.1176/ajp.2006.163.11.1905Search in Google Scholar PubMed

27. Reis M, Lundmark J, Björk H, Bengtsson F. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 2002;24:545–53.10.1097/00007691-200208000-00014Search in Google Scholar PubMed

28. Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000;22:202–8.10.1097/00007691-200004000-00011Search in Google Scholar PubMed

29. Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 2001;15:643–69.10.2165/00023210-200115080-00007Search in Google Scholar PubMed

30. Kandhwal K, Dey S, Nazarudheen S. Establishing bioequivalence of racemic venlafaxine formulations using stereoselective assay method: is it necessary? Chirality 2011;23:948-54.10.1002/chir.21021Search in Google Scholar PubMed

31. Debonnel G, Saint-André E, Hébert C, de Montigny C, Lavoie N, Blier P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007;10:51–61.10.1017/S1461145705006413Search in Google Scholar PubMed

32. Geber C, Ostad Haji E, Schlicht K, Hiemke C, Tadić A. Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder. Ther Drug Monit 2013;35:279–82.10.1097/FTD.0b013e31828816e0Search in Google Scholar PubMed

33. Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 2009;24:250–6.10.1097/YIC.0b013e32832e5b0dSearch in Google Scholar PubMed

34. Crisafulli C, Fabbri C, Porcelli S, Drago A, Spina E, De Ronchi D, et al. Pharmacogenetics of antidepressants. Front Pharmacol 2011;2:6.10.3389/fphar.2011.00006Search in Google Scholar PubMed PubMed Central

35. Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther 2009;124:57–73.10.1016/j.pharmthera.2009.06.007Search in Google Scholar PubMed

36. Philip NS, Carpenter LL, Tyrka AR, Price LH. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother 2010;11:709–22.10.1517/14656561003614781Search in Google Scholar PubMed PubMed Central

37. Wijnen PA, Limantoro I, Drent M, Bekers O, Kuijpers PM, Koek GH. Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity. Ann Clin Biochem 2009;46:527–30.10.1258/acb.2009.009003Search in Google Scholar

38. D’Empaire I, Guico-Pabia CJ, Preskorn SH. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant? J Psychiatry Pract 2011;17:330–9.10.1097/01.pra.0000405363.95881.01Search in Google Scholar

39. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289–304.10.1016/S0149-2918(03)80220-5Search in Google Scholar

40. Kleine-Budde K, Müller R, Kawohl W, Bramesfeld A, Moock J, Rössler W. The cost of depression – a cost analysis from a large database. J Affect Disord 2013;147:137–43.10.1016/j.jad.2012.10.024Search in Google Scholar PubMed

41. Kirchheiner J, Nickchen K, Bauer M, Wong M-L, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442–73.10.1038/sj.mp.4001494Search in Google Scholar PubMed

42. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007;113: 134–53.10.1016/j.pharmthera.2006.07.002Search in Google Scholar PubMed

43. Gervasini G, Benítez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol 2010;66:755–74.10.1007/s00228-010-0857-7Search in Google Scholar PubMed

44. European Medicines Agency. Summary of product characteristics – Efexor. Available from: www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Efexor_30/WC500007863.pdf. Accessed on 26 May, 2013.Search in Google Scholar

45. Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998;34:281–302.10.2165/00003088-199834040-00002Search in Google Scholar PubMed

46. Hermann M, Hendset M, Fosaas K, Hjerpset M, Refsum H. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol 2008;64:483–7.10.1007/s00228-007-0453-7Search in Google Scholar PubMed

47. Troy SM, Parker VP, Hicks DR, Pollack GM, Chiang ST. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. J Clin Pharmacol 1997;37:954–61.10.1002/j.1552-4604.1997.tb04270.xSearch in Google Scholar PubMed

48. Aboelwafa AA, Basalious EB. Optimization and in vivo pharmacokinetic study of a novel controlled release venlafaxine hydrochloride three-layer tablet. AAPS PharmSciTech 2010;11:1026–37.10.1208/s12249-010-9467-zSearch in Google Scholar PubMed PubMed Central

49. Carrasco JL, Díaz-Marsá M, López-Ibor JJ. Effects of venlafaxine extended release formulation on the clinical management of patients. Actas Esp Psiquiatr 2005;33:147–53.Search in Google Scholar

50. DeVane CL. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry 2003;64:14–19.Search in Google Scholar

51. Ilett KF, Hackett LP, Dusci LJ, Roberts MJ, Kristensen JH, Paech M, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998;45:459–62.10.1046/j.1365-2125.1998.00710.xSearch in Google Scholar PubMed PubMed Central

52. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005;28:137–52.10.2165/00002018-200528020-00005Search in Google Scholar PubMed

53. Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009;42:95–100.10.1055/s-0028-1103296Search in Google Scholar PubMed

54. Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, Mullan MJ, Levin GM. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos 2011;32:233–44.10.1002/bdd.753Search in Google Scholar PubMed

55. Wikinski S. Pharmacokinetic mechanisms underlying resistance in psychopharmacological treatment. The role of P-glycoprotein. Vertex 2005;16:438–41.Search in Google Scholar

56. Thuerauf N, Fromm MF. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci 2006;256:281–6.10.1007/s00406-006-0662-6Search in Google Scholar PubMed

57. O’Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol 2012;165:289–312.10.1111/j.1476-5381.2011.01557.xSearch in Google Scholar PubMed PubMed Central

58. Karlsson L, Hiemke C, Carlsson B, Josefsson M, Ahlner J, Bengtsson F, et al. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology 2011;215:367–77.10.1007/s00213-010-2148-5Search in Google Scholar PubMed

59. Weiss J, Dormann SG, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003;305:197–204.10.1124/jpet.102.046532Search in Google Scholar PubMed

60. Ehret MJ, Levin GM, Narasimhan M, Rathinavelu A. Venlafaxine induces P-glycoprotein in human Caco-2 cells. Hum Psychopharmacol 2007;22:49–53.10.1002/hup.820Search in Google Scholar PubMed

61. Porcelli S, Fabbri C, Spina E, Serretti A, De Ronchi D. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol 2011;7:1101–15.10.1517/17425255.2011.597740Search in Google Scholar

62. Kingbäck M, Karlsson L, Zackrisson A-L, Carlsson B, Josefsson M, Bengtsson F, et al. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood. Forensic Sci Int 2012;214:124–34.10.1016/j.forsciint.2011.07.034Search in Google Scholar

63. Zhou S-F, Liu J-P, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:89–295.10.1080/03602530902843483Search in Google Scholar

64. Van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 2005;27:478–83.10.1097/01.ftd.0000162868.84596.c3Search in Google Scholar

65. Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 2000;56:175–80.10.1007/s002280050737Search in Google Scholar

66. Klamerus KJ, Parker VD, Rudolph RL, Derivan AT, Chiang ST. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 1996;16:915–23.Search in Google Scholar

67. Unterecker S, Hiemke C, Greiner C, Haen E, Jabs B, Deckert J, et al. The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. Pharmacopsychiatry 2012;45:229–35.10.1055/s-0031-1301366Search in Google Scholar

68. Unterecker S, Deckert J, Pfuhlmann B. No influence of body weight on serum levels of antidepressants. Ther Drug Monit 2011;33:730–4.10.1097/FTD.0b013e318237b0faSearch in Google Scholar

69. Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3–5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant 2012;27:3736–45.10.1093/ndt/gfs295Search in Google Scholar

70. Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008;30:1206–27.10.1016/S0149-2918(08)80047-1Search in Google Scholar

71. Kennedy SH, McCann SM, Masellis M, McIntyre RS, Raskin J, McKay G, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002;63:181–6.10.4088/JCP.v63n0302Search in Google Scholar PubMed

72. Andrade C. Augmentation of venlafaxine with bupropion: risks associated with a triple monoamine reuptake inhibition approach to partially responsive depression. J Clin Psychiatry 2013;74:e119–21.10.4088/JCP.13f08348Search in Google Scholar

73. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011;44:195–235.10.1055/s-0031-1286287Search in Google Scholar

74. Jones SL, Athan E, O’Brien D. Serotonin syndrome due to co-administration of linezolid and venlafaxine. J Antimicrob Chemother 2004;54:289–90.10.1093/jac/dkh257Search in Google Scholar

75. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008;57:203–9.10.1016/j.neuron.2007.11.017Search in Google Scholar

76. Weizman S, Gonda X, Dome P, Faludi G. Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder. Neuropsychopharmacol Hung 2012;14:87–101.Search in Google Scholar

77. Mitchell PB. Therapeutic drug monitoring of non-tricyclic antidepressant drugs. Clin Chem Lab Med 2004;42:1212–18.10.1515/CCLM.2004.243Search in Google Scholar

78. Llerena A, Berecz R, de la Rubia A, Norberto MJ, Benítez J. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit 2000;22:397–401.10.1097/00007691-200008000-00006Search in Google Scholar

79. LLerena A, Berecz R, de la Rubia A, Fernández-Salguero P, Dorado P. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit 2001;23:616–20.10.1097/00007691-200112000-00004Search in Google Scholar

80. LLerena A, Berecz R, Dorado P, de la Garza CS, Norberto MJ, Cáceres M, et al. Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. J Chromatogr B Anal Technol Biomed Life Sci 2003;783:213–19.10.1016/S1570-0232(02)00661-XSearch in Google Scholar

81. Zourková a, Hadasová E. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. Gen Physiol Biophys 2003;22:103–13.Search in Google Scholar

82. Baumann P, Ulrich S, Eckermann G, Gerlach M, Kuss H-J, Laux G, et al. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci 2005;7:231–47.10.31887/DCNS.2005.7.3/pbaumannSearch in Google Scholar

83. Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007;63:321–33.10.1007/s00228-006-0250-8Search in Google Scholar PubMed

84. Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, et al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics 2012;12:176–83.10.1038/tpj.2010.85Search in Google Scholar PubMed

85. González I, Peñas-Lledó EM, Pérez B, Dorado P, Alvarez M, LLerena A. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 2008;9:833–40.10.2217/14622416.9.7.833Search in Google Scholar PubMed

86. Jurica J, Bartecek R, Zourkova A, Pindurova E, Sulcova A, Kasparek T, et al. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice. J Clin Pharm Ther 2012;37:486–90.10.1111/j.1365-2710.2012.01333.xSearch in Google Scholar PubMed

87. Nichols AI, Lobello K, Guico-Pabia CJ, Paul J, Preskorn SH. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. J Clin Psychopharmacol 2009;29:383–6.10.1097/JCP.0b013e3181acc4ddSearch in Google Scholar PubMed

88. Llerena A, Dorado P, Peñas-Lledó EM. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 2009;10:17–28.10.2217/14622416.10.1.17Search in Google Scholar PubMed

89. Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 2006;39:121–7.10.1055/s-2006-946701Search in Google Scholar PubMed

90. Kandasamy M, Srinivas P, Subramaniam K, Ravi S, John J, Shekar R, et al. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes – focus on venlafaxine and O-desmethylvenlafaxine. Eur J Clin Pharmacol 2010;66:879–87.10.1007/s00228-010-0829-ySearch in Google Scholar PubMed

91. Dorado P, Machín E, de Andrés F, Naranjo M-E, Peñas-Lledó EM, Llerena A. Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes. Drug Metabol Drug Interact 2012;27:217–33.10.1515/dmdi-2012-0018Search in Google Scholar PubMed

92. Lessard E, Yessine MA, Hamelin BA, O’Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999;9:435–43.Search in Google Scholar

93. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine M-A, O’Hara G, et al. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 2003;13:39–47.10.1097/00008571-200301000-00006Search in Google Scholar PubMed

94. Whyte EM, Romkes M, Mulsant BH, Kirshne MA, Begley AE, Reynolds CF, et al. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry 2006;21:542–9.10.1002/gps.1522Search in Google Scholar PubMed

95. McAlpine DE, O’Kane DJ, Black JL, Mrazek DA. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc 2007;82:1065–8.10.4065/82.9.1065Search in Google Scholar PubMed

96. Gareri P, De Fazio P, Gallelli L, De Fazio S, Davoli A, Seminara G, et al. Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation. Ann Pharmacother 2008;42:434–8.10.1345/aph.1K405Search in Google Scholar PubMed

97. Grasmäder K, Verwohlt PL, Rietschel M, Dragicevic A, Müller M, Hiemke C, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004;60:329–36.10.1007/s00228-004-0766-8Search in Google Scholar PubMed

98. PharmGKB. Venlafaxine. Available from: http://www.pharmgkb.org/drug/PA451866. Accessed on 28 July, 2013.Search in Google Scholar

99. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 2013;17:165–84.10.1007/s40291-013-0028-5Search in Google Scholar PubMed PubMed Central

100. Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010;71:1482–7.10.4088/JCP.08m04773bluSearch in Google Scholar PubMed

101. Mulder H, Wilmink FW, Beumer TL, Tamminga WJ, Jedema JN, Egberts AC. The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study. J Clin Psychopharmacol 2005;25:188–91.10.1097/01.jcp.0000155832.79777.b5Search in Google Scholar PubMed

102. Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004;59:803–7.Search in Google Scholar